103 results
S-3ASR
RVMD
Revolution Medicines Inc
8 May 24
Automatic shelf registration
5:11pm
, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens.
Our research and development pipeline comprises
8-K
EX-99.1
RVMD
Revolution Medicines Inc
8 May 24
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
4:05pm
was due to the termination of the company’s collaboration agreement with Sanofi in 2023.
R&D Expenses: Research and development expenses were $118.0 … :
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense), net:
Interest income
Interest
S-3ASR
j4r6gmfvsc3 kk39n
4 Mar 24
Automatic shelf registration
5:23pm
S-3ASR
EX-99.3
a4ng4qur1n98ecu62
4 Mar 24
Automatic shelf registration
5:23pm
8-K
EX-99.1
517o8m5i 89mj
26 Feb 24
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
4:04pm
8-K/A
EX-99.3
2soeyli65h5dhi6
22 Dec 23
Financial Statements and Exhibits
5:45pm
8-K
EX-99.1
xdpsim
6 Nov 23
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
4:05pm
DEFA14A
rinwyp0m4am oxo3
1 Nov 23
Additional proxy soliciting materials
7:15am
425
np93mp mdb0
1 Nov 23
Business combination disclosure
7:11am
8-K
EX-99.1
qp5o v9qtkqa15
1 Nov 23
Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112
7:08am
8-K
xb0gv7cnh cb
1 Nov 23
Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112
7:08am
425
hy30o5n
23 Oct 23
Business combination disclosure
6:13am
DEFM14A
d4y03bsg2y7k6
29 Sep 23
Proxy related to merger
4:19pm
424B3
806z3pblfjh232zteib
29 Sep 23
Prospectus supplement
4:17pm
S-4/A
w7nhd5zk
27 Sep 23
Registration of securities issued in business combination transactions (amended)
5:25pm